Tredegar Corporation (TG) director William M. Gottwald reported recent insider stock sales. On 11/13/2025, an indirect account sold 27 shares of Tredegar common stock at $8.50 per share. On 11/14/2025, an indirect account sold 9,998 shares at a weighted average price of $8.516, with individual sale prices ranging from $8.50 to $8.54.
After these transactions, one indirect holding shown in the table held 744,948 shares of Tredegar common stock, reported as owned as co-trustee of the Residual 10-Year CLAT UA FDGJR Living Trust. Additional indirect holdings disclosed include 6,197 shares owned by his wife, 847,470 shares held as co-trustee for a family trust, and 211,260 shares held as trustee of the William Michael Gottwald Revocable Trust, with beneficial ownership of the wife’s shares disclaimed.
Tredegar Corp (TG): Director insider sale disclosed. Director William M. Gottwald reported an indirect sale of Tredegar common stock on 11/12/2025. He sold 2,387 shares at $8.50 per share (transaction code S) through a trust where he serves as co‑trustee, the Residual 10‑Year CLAT UA FDGJR Living Trust. Following the sale, that trust held 754,973 shares.
Other indirect holdings reported include 6,197 shares owned by his wife, 847,470 shares held as co‑trustee for a family trust under the will of Floyd D. Gottwald, and 211,260 shares held by the William Michael Gottwald Revocable Trust.
Tredegar (TG) insider John D. Gottwald reported an open‑market sale of 2,388 shares of Tredegar Common Stock on 11/12/2025 at $8.5, executed from the Residual 10‑Year CLAT UA FDGJR Living Trust.
Following the transaction, he reported 1,917,639 shares beneficially owned directly, and indirect holdings of 12,953 (owned by wife), 90,000 (Family Trust FBO children), 847,470 (as co‑trustee), and 754,973 (as co‑trustee of the CLAT trust).
Tredegar Corp (TG) director reported a Form 4 sale of Tredegar common stock. On 11/12/2025, the reporting person sold 2,388 shares at $8.50 via an indirect account held as co-trustee of the Residual 10-year CLAT UA FDGJR Living Trust. That account held 754,973 shares after the trade.
Other reported holdings include 40,000 shares directly, 847,469 as co‑trustee FBO family u/w Floyd D. Gottwald, 10,000 owned by spouse, and 90,000 as co‑trustee of the John D. Gottwald Family Trust.
TG filed a Form 144 notice for a proposed sale of 349,106 shares of common stock, with an aggregate market value of $2,195,875.00. The filing lists Truist Investment Services Inc. as broker and the NYSE as the exchange, with an approximate sale date of 11/10/2025.
The shares were originally acquired by the FDGJr Living Trust in January 2022 and recorded as an inheritance with a payment date of 01/29/2024. As context, 34,910,693 shares were outstanding. Recent sales over the past three months included multiple transactions by a related trust, reflecting ongoing disposition activity.
Tredegar Corporation furnished a press release announcing its results of operations for the third quarter ended September 30, 2025. The release is provided as Exhibit 99 to this report.
Consistent with Item 2.02 treatment, the information in this report, including Exhibit 99, is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act, nor incorporated by reference into other filings except as specifically stated.
Tredegar Corporation (TG) reported a strong turnaround in Q3 2025. Sales rose to $194.9 million from $146.1 million, and net income from continuing operations improved to $7.1 million ($0.20 per diluted share) from a loss a year ago. Gross margin expanded to 16.0% from 12.4% as volumes and pricing improved, particularly in Aluminum Extrusions.
Aluminum Extrusions delivered EBITDA from ongoing operations of $16.8 million (vs. $6.2 million), driven by higher volume and favorable pricing, while PE Films posted $7.2 million (vs. $5.9 million). Nine-month sales reached $538.8 million (vs. $444.0 million) with net income from continuing operations of $9.6 million. Including discontinued operations, nine-month net income was $18.9 million, reflecting the completed sale of Terphane.
Liquidity improved: cash was $13.3 million (vs. $7.1 million at year-end), ABL revolver borrowings were $49.5 million (vs. $60.6 million), and availability under the $125 million ABL Facility was $72.5 million. Operating cash flow for the first nine months was $17.3 million (vs. $6.1 million). Shares outstanding were 34,910,693 as of October 31, 2025.
Tredegar Corporation reported that D. Andrew Edwards, its Executive Vice President and Chief Financial Officer, informed the company on October 1, 2025 of his intention to retire, with an effective retirement date of December 31, 2025. The notice establishes a defined timeline for a CFO transition over roughly three months. This filing does not include information about a successor, departure reasons, or any interim arrangements, so the operational and financial impacts will depend on subsequent disclosures about succession planning and transition execution.
George C. Freeman III, a director of Tredegar Corp (TG), purchased 2,844 shares of Tredegar common stock on 10/01/2025 at a price of $7.91 per share. After the transaction, the reporting person beneficially owned 75,562 shares. The Form 4 was filed as a single reporting person filing and the signature on the form is by an attorney-in-fact, Kevin C. Donnelly, dated 10/03/2025. No derivative securities were reported on this Form 4.
Christine R. Vlahcevic, a director of Tredegar Corporation (TG), reported a personal purchase of 2,844 shares of Tredegar common stock on 10/01/2025 at a price of $7.91 per share. After the transaction she beneficially owned 7,986 shares. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing shows a straightforward open-market acquisition with no derivatives, amendments, or additional explanatory text provided.